Tag: serotonin and carcinoid syndrome

lexicon telestar 2

Lexicon Pharmaceuticals, Inc. Continues Recruiting for Phase 3 Studies in Carcinoid Syndrome

August 20, 2014

Many patients face the challenge of controlling carcinoid syndrome which can persist even while being treated with somatostatin analog (SSA) therapy. For patients on SSA therapy who continue to experience conditions such as diarrhea, frequent bowel…

READ MORE
telotristat etiprate clinical trial

Discover Something New in Carcinoid Syndrome

November 11, 2013

For patients who suffer from carcinoid syndrome – with symptoms such as diarrhea, frequent bowel movements, abdominal pain, and flushing – that is not adequately controlled by their current somatostatin analog therapy, there is an opportunity to participate…

READ MORE
pablo lapuerta md

Lexicon Pharmaceuticals Begins Phase 3 Clinical Trial of Telotristat Etiprate in Patients with Carcinoid Syndrome

December 4, 2012

Patients with metastatic carcinoid syndrome will have the opportunity to participate in a new Phase 3 clinical trial of Lexicon Pharmaceutical’s telotristat etiprate (LX1032), an oral drug candidate designed to treat carcinoid syndrome by reducing…

READ MORE
lexicon headquarters

Lexicon Pharmaceuticals Granted Orphan Drug Designation by FDA for Carcinoid Syndrome Treatment

April 2, 2012

Lexicon Pharmaceuticals, Inc. has been granted Orphan Drug Designation for telotristat etiprate (LX1032) by the U.S. Food and Drug Administration (FDA).  LX1032 is used to treat carcinoid syndrome, a chronic condition caused by neuroendocrine tumors,…

READ MORE